Nagy, Janice A.
Semple, Carson
Riveros, Daniela
Sanchez, Benjamin
Rutkove, Seward B.
Funding for this research was provided by:
National Institutes of Health (R01 NS091159)
Article History
Received: 31 August 2021
Accepted: 14 March 2022
First Online: 29 March 2022
Competing interests
: Dr. Rutkove has equity in, and serves a consultant and scientific advisor to Myolex, Inc., a company that designs impedance devices for clinical and research use; he is also a member of the company’s Board of Directors. The company also has an option to license patented impedance technology of which Dr. Rutkove is named as an inventor. Dr. Sanchez holds equity in Haystack Dx, Inc., a company that develops clinical needle impedance technology for neuromuscular evaluation. The company has an option to license patented needle impedance technology where the author is named an inventor. He also holds equity and serves as Scientific Advisory Board Member of Ioniq Sciences, Inc., a company that develops clinical impedance technology for early cancer detection. Dr. Sanchez serves as Scientific Advisory Board Member of B-Secur, Ltd., a company that develops wearable ECG and impedance technology. He consults for Myolex, Inc., a company that develops surface EIM technology. The company has an option to license patented surface impedance technology where the author is named an inventor. Dr. Sanchez also serves as a consultant to Impedimed, Inc., a company that develops clinical impedance technology. The company patented impedance technology where the author is named an inventor. He also serves as consultant to Texas Instruments, Inc., Happy Health, Inc., and Maxim Integrated, Inc., companies that develop impedance related technology for consumer use. The other authors (JN, CS, DR) declare no competing interests.